Healthier World with Quest Diagnostics

Action from Insight: Tackling Insulin Resistance (18 min)

Identifying insulin resistance offers significant—and often untapped—clinical value and can help healthcare providers and their patients take action with diet and lifestyle choices to avoid or change the progression to prediabetes and diabetes. Today’s episode features Patty Bianchi, Registered Dietitian Nutritionist and Certified Diabetes Care and Education Specialist and Trisha Winchester, PhD, Quest Diagnostics Sr Manager for Clinical & Education.
This episode will
Review glucose regulation by insulin (1:15) 
Discuss how insulin resistance is measured (3:00) 
Review actionable ways to reduce insulin resistance through lifestyle (4:00), exercise (6:30), diet (8:50), stress and sleep (11:50)
Discuss the 4myheart patient education program offered through Quest Diagnostics Center of Excellence at Cleveland Heartlab (14:30)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
 
Date: 11/2024
Contributor(s): Patty Bianchi, Trisha Winchester, PhD
Additional Resources:
Podcast: The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions (17 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics

The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions (17 min)

Metabolic dysfunction is a common root cause of many cardiometabolic conditions that burden the healthcare system. This episode will address insulin resistance, a syndrome that underlies metabolic dysfunction, and how tools can catch risk early, allowing actions that may prevent and reverse the onset of chronic illness. Today’s episode is with Quest Diagnostics experts Kenneth French, Senior Clinical Consultant, and Dr Maeson Latsko, clinical and education specialist. 
This episode will
Identify how early identification of insulin resistance can prevent the rise in metabolic dysfunction and Type II Diabetes (3:00)
Describe the insulin resistance panel with score (8:11) 
Elucidate how identifying insulin resistance can prevent other chronic illness, such as liver related disorders and kidney disease (12:41) 
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
 
Date: 09/2024
Contributor(s): Kenneth French, Maeson Latsko, PhD
Additional Resources:
Podcast: Action from Insight: Tackling Insulin Resistance (18 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
 
 
 
 
References:
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301
Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107
Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab417
Healy, M. By 2030, nearly half of all U.S. adults will be obese, experts predict. New York Times. https://www.latimes.com/science/story/2019-12-18/nearly-half-of-us-adults-will-be-obese-by-2030
Khan RMM, Chua ZJY, Tan JC, et al. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9):546. doi:10.3390/medicina55090546

Instant Insights: Apolipoprotein B (7 min)

Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Apolipoprotein B (ApoB)—containing lipoproteins more closely identifies atherosclerosis and correlates to atherogenic particles in circulation.
This episode will:
Review the current state of cardiovascular risk assessment
Describe lipoprotein anatomy and ApoB
Identify discordance between LDL cholesterol and ApoB
Discuss the guideline recommended clinical utility of ApoB in risk identification
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Contributor(s): Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Ordering information: Apolipoprotein B | Test Detail | Quest Diagnostics
Apolipoprotein B | Test Summary | Quest Diagnostics
Apo B and cardiovascular risk | Quest Diagnostics | Quest Diagnostics
 
References:
 
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ: Cardiovascular Quality and Outcomes. 2011;4(3):337-345. doi:10.1161/CIRCOUTCOMES.110.959247
 
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423
 
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
 
Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356

Instant Insights: Lipoprotein (a) (6 min)

Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Lipoprotein (a), or Lp(a), is a particularly atherogenic type of lipoprotein, where excess levels significantly influence cardiovascular risk.  
This episode will:
Review the significant cardiovascular implications of Lp(a) excess
Describe Lp(a) structure
Discuss how Lp(a) is measured
Review the treatment landscape for Lp(a)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Contributor(s): Dr. Maeson Latsko
 
Additional Resources:
Ordering information: Lipoprotein (a) | Test Detail | Quest Diagnostics
Lipoprotein(a) | Test Summary | Quest Diagnostics
 
Quest Diagnostics Clinical Education Center [Link]
 
 
References:
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(A) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010 
 
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001

Laboratory assessment in the diagnosis of male hypogonadism (16 min)

Hypogonadism is a common condition in the male population, impacting approximately 35% of men over 45 years of age. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Maeson Latsko, PhD, clinical specialist.
This episode will:
Review the clinical and biochemical changes seen in male patients with hypogonadism (1:20)
Discuss the guideline-recommended methodologies for testosterone analysis (3:24)
Learn how to delineate between primary and secondary hypogonadism (7:38)
To learn more, please view the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: May 3, 2024
Contributor(s): Dr. Sanjay Dixit, MD, Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center 
Quest Diagnostics Hypogonadism FAQs
Clinical Focus: Hypogonadism and Low Testosterone in Men 
Adult Male Hypogonadism Diagnostic Algorithm
References See Quest Diagnostics Clinical Education Center 

Laboratory testing for the diagnosis and management of thyroid disorders (21 min)

An estimated 20 million Americans have some form of thyroid disease, and up to 60% of them are unaware of their condition. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist. 
 
This episode will:
Identify common signs and symptoms of thyroid dysfunction
Identify lab recommendations to support the diagnosis of hypo- and hyperthyroidism
Discuss the association between cardiometabolic conditions and thyroid dysfunction
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions. 
 
Date: 4/18/2024
Contributor(s): Dr. Sanjay Dixit, MD, Sarah Walsh, PA-C, CLS 
Additional Resources: 
Quest Diagnostics Clinical Education Center
Quest Diagnostics Thyroid Disorders 
Clinical Focus: Thyroid Dysfunction in Nonpregnant Adults
Testing Algorithm for Thyroid Dysfunction in Nonpregnant Adults
References See Quest Diagnostics Clinical Education Center

Laboratory assessment in PCOS diagnosis and management (19 min)

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine diagnoses for reproductive-aged women and carries lifelong cardiometabolic risk. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist.
This episode will:
Review the diagnostic criteria for PCOS (2:00)
Identify lab recommendations to support the diagnosis of PCOS (6:00)
Discuss associated cardiometabolic conditions and how to screen and monitor for these conditions (14:45)
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date recorded: 4/9/2024
Contributor(s): Dr. Sanjay Dixit, MD, Sarah Walsh, PA-C, CLS
Additional Resources:
Quest Diagnostics Polycystic ovary syndrome
Clinical Focus: Polycystic Ovary Syndrome 
Polycystic Ovary Syndrome (PCOS) Diagnostic Algorithm
Laboratory Testing in the Differential Diagnosis of PCOS and NCCAH
References See Quest Diagnostics Clinical Education Center